RQI Pediatric Advanced Life Support (PALS) Practice Test

Delivering bronchodilator therapy in a pediatric asthma flare should provide rapid, direct relief to the airways. Inhaled short-acting beta-agonists delivered by a nebulizer or a metered-dose inhaler with a spacer act quickly on airway smooth muscle, producing fast bronchodilation with minimal systemic exposure. This direct delivery is particularly important in children, where swift improvement of wheeze and breathlessness is needed and coordination can be a challenge—nebulizers are often easier for younger kids, while a spacer with an inhaler makes correct dosing more accessible for others.

Oral syrup bronchodilators reach the bloodstream more slowly and with less predictable absorption, so they’re not ideal for rapid relief during an acute episode. Intravenous albuterol is reserved for severe, life-threatening cases where inhaled therapy isn’t feasible or hasn’t controlled the symptoms, and it carries a greater risk of systemic side effects. Subcutaneous albuterol is not a standard first-line option for routine pediatric asthma flares due to less reliable bronchodilation and more systemic exposure. In short, inhaled therapy via nebulizer or spacer-delivered MDI provides the quickest, most effective relief in pediatric asthma episodes.